Sleep Disorders

September 21st 2025

New phase 3 data reveals seltorexant's potential as a safer adjunctive treatment for major depressive disorder with insomnia, despite not meeting its primary end point.

September 12th 2025

Cognitive behavioral therapy for insomnia effectively treats chronic insomnia, promoting long-term sleep improvement through targeted behavioral strategies.

September 10th 2025

Takeda's oveporexton shows promising results in treating narcolepsy type 1, significantly improving symptoms and quality of life in clinical trials.

September 9th 2025

Alixorexton shows promise as a treatment for narcolepsy type 1, and is the first orexin 2 receptor agonist to demonstrate clinically meaningful and statistically significant impact on wakefulness, cognition, and fatigue with once-daily dosing across a range of doses.